Prof. Dr. Eva Susanne Dietrich works at the interface of evidence-based medicine, health economics, statutory reimbursement, and pharmaceutical regulation, with a particular focus on pharmaceutical market access, benefit assessment, and health policy in Germany. She brings more than 25 years of experience across academia, healthcare self-governance, statutory health insurance, and strategic market access consulting.
In earlier roles, she served as Head of the Department of Drugs, Remedies and Aids at the National Association of Statutory Health Insurance Physicians (KBV) and as a deputy member of the Federal Joint Committee (G-BA), the central decision-making body for reimbursable healthcare services in German statutory health insurance. She also contributed to G-BA subcommittee work on medicines and rules of procedure and participated in expert work on off-label drug use on behalf of the Federal Institute for Drugs and Medical Devices (BfArM).
She subsequently established and directed a scientific institute for one of Germany’s largest statutory health insurance funds and headed its Management Division Health Sciences. This role provided her with a comprehensive payer-side perspective on healthcare data, contractual arrangements, provider collaboration, and the practical implementation of statutory healthcare responsibilities.
Since 2018, she has been founder and head of the Institute for Evidence-based Positioning in the Healthcare Sector. As an independent consultant, she advises pharmaceutical companies and consulting firms on AMNOG strategy, benefit assessment, pricing and reimbursement, evidence generation, early consultations, dossier strategy, G-BA hearings, and negotiation preparation.
Eva Susanne Dietrich holds an honorary professorship at the University of Bonn, where she teaches health economics, evidence-based medicine, benefit assessment, and drug regulatory affairs. Her academic work focuses on the assessment of medical innovation, the methodological foundations of benefit evaluation, and the translation of clinical evidence into healthcare decision-making. She studied pharmacy at the University of Heidelberg, obtained her PhD in pharmacoeconomic methodology, and holds a Master’s degree in Health Technology Assessment and Management from the University of Barcelona.